الفهرس 
• AIM OFWORKOnly 14 pages are availabe for public view
 |  | from | 90 |  |  |
| | | from | 90 | | |
Abstract
SLE patients suffer from multi-organ involvement and have a high degree of inflammation with elevated acute phase reactants. This may have a bearing on the increased frequency of coronary artery disease and stroke observed in SLE patients. Up to now, the research on SLE and dyslipidemia has been fairly limited compared to that done regarding other side effects such as increased infections, a vascular necrosis and steroid induce osteoporosis.
This study was conducted to detect the prevalence of dyslipidemia in SLE patients in the Suez Canal University Hospital and to determine the possible contributing factors to dyslipidemia such as corticosteroids use, presence of renal disease and lupus activity.
One-third of the patients (33.3%) had low disease activity (SLEDAI<2), 18.1% of them were inactive (SLEDAI=0). Fifty percent of the patients had renal involvement. The majority of the patients (80.6%) administered hydroxychloroquine with a dose ranged from 200-400 mg and 90.3% of them administered steroids with a dose ranged from 10-60 mg.
Overall prevalence of dyslipidemia among patients was 65.3%. The prevalence of hypercholesteremia was 41.7%, hypertriglyceridemia was 43.1%, low HDL was 25% and high LDL was 31.9%.
There was insignificant difference between patients with and without dyslipidemia regarding median age (p=0.48). There was statistically significant higher median duration among patients with dyslipidemia in comparison to patients without (p=0.027).